The strong clinical data for casdatifan could drive investor interest despite declining revenue, but traders should monitor upcoming data readouts in 2026 and the futility analysis of the STAR-121 program which could impact R&D expense trajectory.
Price Chart
Executive Summary
Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical data for its drug candidate casdatifan in kidney cancer, including a median progression-free survival of 15.1 months and a 45% response rate. The company maintains a robust $1 billion cash position with runway into 2028, while R&D expenses increased to $121 million in Q4. Revenue declined slightly to $33 million from $36 million year-over-year.
Key Financial Metrics
Key Facts
- Updated data for casdatifan showed 15.1 months median PFS and 45.2% confirmed response rate in 100mg cohort
- Cash, cash equivalents and marketable securities were $1.0 billion as of December 31, 2025
- Q4 2025 revenue was $33 million, down from $36 million in Q4 2024
- Q4 2025 R&D expenses were $121 million, up from $111 million in Q4 2024
- Net loss was $106 million for Q4 2025, compared to $94 million for Q4 2024
- Company expects cash runway until at least second half of 2028
Financial Impact
Revenue decreased by $3 million year-over-year while R&D expenses increased by $10 million, resulting in a wider net loss of $106 million (up from $94 million)
Risk Factors
- R&D expenses increased while revenue declined, widening net loss
- Futility analysis of STAR-121 program could lead to termination of key development program
- Dependence on successful clinical trial outcomes for casdatifan and quemliclustat
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000007 |
| Document: 0001724521-26-000007-index-headers.html | 0001724521-26-000007 |
| Document: 0001724521-26-000007-index.html | 0001724521-26-000007 |
| Document: 0001724521-26-000007.txt | 0001724521-26-000007 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 144 | $28.92 $28.62 | ▼ −1.04% | ▼ −3.46% | $24.37 (−15.73%) |
Apr 21, 2026 23w ago | DEFA14A | $26.62 $22.75 | ▼ −14.54% | ▼ −17.70% | $24.37 (−8.45%) |
Apr 20, 2026 23w ago | 8-K | $22.74 $23.40 | ▼ −2.90% | ▲ +1.30% | $24.37 (−7.17%) |
Apr 8, 2026 25w ago | 144 | $23.28 $26.00 | ▲ +11.68% | ▲ +4.12% | $24.37 (+4.68%) |
Feb 25, 2026 31w ago | 8-K | $20.27 $21.46 | ▲ +5.87% | ▲ +11.11% | $24.37 (+20.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access